1.03
price down icon3.74%   -0.04
after-market Dopo l'orario di chiusura: 1.05 0.02 +1.94%
loading
Precedente Chiudi:
$1.07
Aprire:
$1.04
Volume 24 ore:
100.39K
Relative Volume:
0.06
Capitalizzazione di mercato:
$5.62M
Reddito:
-
Utile/perdita netta:
$-17.06M
Rapporto P/E:
-0.0146
EPS:
-70.7173
Flusso di cassa netto:
$-14.18M
1 W Prestazione:
-6.36%
1M Prestazione:
+0.00%
6M Prestazione:
-81.61%
1 anno Prestazione:
-99.81%
Intervallo 1D:
Value
$1.03
$1.0796
Intervallo di 1 settimana:
Value
$1.03
$1.1499
Portata 52W:
Value
$0.7715
$544.00

Cns Pharmaceuticals Inc Stock (CNSP) Company Profile

Name
Nome
Cns Pharmaceuticals Inc
Name
Telefono
1-800-946-9185
Name
Indirizzo
2100 WEST LOOP SOUTH, HOUSTON
Name
Dipendente
4
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-13
Name
Ultimi documenti SEC
Name
CNSP's Discussions on Twitter

Confronta CNSP con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
CNSP
Cns Pharmaceuticals Inc
1.03 6.01M 0 -17.06M -14.18M -70.72
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.58 26.10B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
442.05 111.96B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.35 42.96M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
81.20 6.39B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.28 63.52B 14.09B 4.50B 2.96B 39.28

Cns Pharmaceuticals Inc Stock (CNSP) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2020-12-28 Downgrade Ladenburg Thalmann Buy → Neutral
2020-08-24 Iniziato Ladenburg Thalmann Buy

Cns Pharmaceuticals Inc Borsa (CNSP) Ultime notizie

pulisher
May 22, 2025

CNS Pharmaceuticals (CNSP) Target Price Increased Amid Focus Shift to TPI-287 | CNSP Stock News - GuruFocus

May 22, 2025
pulisher
May 19, 2025

CNS Pharmaceuticals Stock Declines On Wider Q1 Loss: But Retail Stays Unmoved - Asianet Newsable

May 19, 2025
pulisher
May 16, 2025

CNS Pharmaceuticals (NASDAQ: CNSP) Reports Q1 Loss, Highlights Progress on TPI 287 for Brain Cancer - The Globe and Mail

May 16, 2025
pulisher
May 16, 2025

CNS Pharmaceuticals Stock Declines On Wider Q1 Loss: But Retail Stays Unmoved By Stocktwits - Investing.com India

May 16, 2025
pulisher
May 16, 2025

CNS Pharmaceuticals (CNSP) Advances in Neuro-Oncology with Promi - GuruFocus

May 16, 2025
pulisher
May 16, 2025

CNSP Secures Funding to Support Operations Through 2026 | CNSP S - GuruFocus

May 16, 2025
pulisher
May 16, 2025

CNSP Secures Funding to Support Operations Through 2026 | CNSP Stock News - GuruFocus

May 16, 2025
pulisher
May 16, 2025

CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update | CNSP Stock News - GuruFocus

May 16, 2025
pulisher
May 16, 2025

CNS Pharmaceuticals Secures $18M War Chest to Advance Breakthrough Brain Cancer Treatment - Stock Titan

May 16, 2025
pulisher
May 15, 2025

CNS Pharmaceuticals Raises $5M in Public Offering - TipRanks

May 15, 2025
pulisher
May 14, 2025

CNS Pharmaceuticals (NASDAQ: CNSP) Prices $5 Million Public Offering with Institutional Investor - The Globe and Mail

May 14, 2025
pulisher
May 14, 2025

Health Care Stocks Face Broad Downturn As Sector Challenges Mount - Finimize

May 14, 2025
pulisher
May 13, 2025

CNS Pharmaceuticals sets terms for $5 million stock offering By Investing.com - Investing.com Canada

May 13, 2025
pulisher
May 13, 2025

CNS Pharmaceuticals (NASDAQ: CNSP) Secures Orphan Drug Designation Transfer for TPI 287 in Brain Cancer Indications - The Globe and Mail

May 13, 2025
pulisher
May 13, 2025

Jazz Pharma. v. Avadel CNS Pharma: Federal Circuit Applies a Fact-Specific Approach to the Patent Infringement Safe Harbor - JD Supra

May 13, 2025
pulisher
May 13, 2025

CNS Pharmaceuticals Soars Over 100% on $5 Million Offering: What’s Driving the Surge? - RagingBull

May 13, 2025
pulisher
May 13, 2025

CNS Pharmaceuticals sets terms for $5 million stock offering - Investing.com

May 13, 2025
pulisher
May 13, 2025

CNS Pharmaceuticals Announces Pricing of $5 Million Public Offer - GuruFocus

May 13, 2025
pulisher
May 13, 2025

CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules | CNSP Stock News - GuruFocus

May 13, 2025
pulisher
May 13, 2025

CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules - Stock Titan

May 13, 2025
pulisher
May 13, 2025

CNSP Gains Key Orphan Drug Designation Transfer for TPI 287 | CN - GuruFocus

May 13, 2025
pulisher
May 13, 2025

CNS Pharmaceuticals Acquires Orphan Drug Designation for TPI 287 in Glioblastoma - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

CNS Pharmaceuticals secures orphan drug status for cancer drug - Investing.com

May 13, 2025
pulisher
May 13, 2025

CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, - GuruFocus

May 13, 2025
pulisher
May 13, 2025

CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287 | CNSP Stock News - GuruFocus

May 13, 2025
pulisher
May 13, 2025

CNS Pharmaceuticals secures orphan drug status for cancer drug By Investing.com - Investing.com Nigeria

May 13, 2025
pulisher
May 13, 2025

CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287 - Stock Titan

May 13, 2025
pulisher
May 09, 2025

CNS Pharma Stock Price, Quotes and Forecasts | NASDAQ:CNSP - Benzinga

May 09, 2025
pulisher
May 07, 2025

Medical Patent Injunction At Odds With Hatch-Waxman, Federal Circuit Finds - Law360

May 07, 2025
pulisher
Apr 29, 2025

Transneural Therapeutics Appoints CNS Drug Development Expert, Mark A. Demitrack, MD, as Chief Research and Development Officer - PR Newswire

Apr 29, 2025
pulisher
Apr 26, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 26, 2025
pulisher
Apr 23, 2025

CNSP stock touches 52-week low at $0.09 amid sharp decline - MSN

Apr 23, 2025
pulisher
Apr 15, 2025

CNSP stock touches 52-week low at $0.99 amid sharp decline - Investing.com

Apr 15, 2025
pulisher
Apr 14, 2025

10 Best Pharma Stocks to Buy for Long Term Growth - Insider Monkey

Apr 14, 2025
pulisher
Apr 09, 2025

CNS Pharmaceuticals Advances TPI 287 for Glioblastoma - TipRanks

Apr 09, 2025
pulisher
Apr 06, 2025

CNS Pharmaceuticals to Report Fourth Quarter 2019 Financial Results on March 12, 2020 - BioSpace

Apr 06, 2025
pulisher
Apr 05, 2025

Financial Survey: KalVista Pharmaceuticals (NASDAQ:KALV) and CNS Pharmaceuticals (NASDAQ:CNSP) - Defense World

Apr 05, 2025
pulisher
Apr 04, 2025

Biopharma Firm Discovers High-Impact CNS Therapy in U.S. With Breakthrough Results - streetwisereports.com

Apr 04, 2025
pulisher
Apr 02, 2025

CNS Pharmaceuticals reports FY24 EPS ($38.87) vs. ($12,509.11) last year - Yahoo Finance

Apr 02, 2025
pulisher
Apr 01, 2025

CNS Pharmaceuticals Reports Full Year 2024 Financial Results - Yahoo Finance

Apr 01, 2025
pulisher
Apr 01, 2025

CNS Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Apr 01, 2025
pulisher
Apr 01, 2025

CNS Pharma's Strategic Shift: New Cancer Drug Focus as Losses Shrink 21% - Stock Titan

Apr 01, 2025
pulisher
Mar 31, 2025

CNS Pharmaceuticals Inc. (CNSP) reports earnings - qz.com

Mar 31, 2025
pulisher
Mar 26, 2025

CNS Pharmaceuticals (NASDAQ:CNSP) Receives Hold Rating from Maxim Group - Defense World

Mar 26, 2025
pulisher
Mar 26, 2025

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP): When Will It Breakeven? - Yahoo Finance

Mar 26, 2025
pulisher
Mar 26, 2025

Market Sentiment Around Loss-Making CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) - simplywall.st

Mar 26, 2025
pulisher
Mar 25, 2025

CNSP stock touches 52-week low at $1.49 amid sharp annual decline By Investing.com - Investing.com South Africa

Mar 25, 2025
pulisher
Mar 25, 2025

12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga

Mar 25, 2025

Cns Pharmaceuticals Inc Azioni (CNSP) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$1.08
price up icon 1.89%
$30.14
price down icon 3.74%
$573.26
price down icon 1.32%
$304.56
price up icon 3.98%
$4.50
price down icon 3.02%
$490.28
price down icon 19.01%
Capitalizzazione:     |  Volume (24 ore):